[Impact of the Subcutaneous Formulation of Daratumumab in the Treatment of Multiple Myeloma: pharmacoeconomic aspects of the new formulation]
DOI:
https://doi.org/10.7175/fe.v27i1.1615Keywords:
Daratumumab, Multiple Myeloma, Micocosting, Subcutaneous, IntravenousAbstract
BACKGROUND: The subcutaneous (SC) formulation of daratumumab substantially shortens administration time compared with the intravenous (IV) formulation and may improve organizational efficiency and reduce treatment-related resource use in hematology units. This study aimed to compare administration-related costs of SC and IV daratumumab at the Hematology Unit of ARNAS Garibaldi Hospital in Catania, Italy.
METHODS: A microcosting analysis adapted Federici et al.'s methodology to the local setting. Published discrete event simulation scenarios from the same study were used to contextualize the potential organizational implications of SC versus IV administration. The analysis included healthcare professional time, preparation and administration materials, drug transport from the centralized antineoplastic drug unit to the day hospital, and healthcare waste disposal. Organizational and time parameters were replaced, whenever available, with 2025 real-world data from the study center.
RESULTS: In 2025, 118 patients with multiple myeloma were treated at the center, including 88 receiving daratumumab, of whom 86 received the SC formulation and were considered in this analysis. Mean body weight was 74.9 kg. Overall, 850 SC administrations were performed: 26 first, 26 second, and 798 subsequent administrations. Administration time was 5 minutes for SC daratumumab, and 420 minutes for the first IV infusion and 300 minutes for subsequent infusions. Administration-related costs for SC totaled €16,048.00. In the counterfactual IV scenario, estimated costs would have been €64,376.58, corresponding to estimated savings of €48,328.58. Following the introduction of SC daratumumab in 2024, treated patients increased from 36 to 93 and remained broadly stable at 88 in 2025.
CONCLUSIONS: In this single-center analysis, SC daratumumab was associated with shorter administration times and lower organizational resource use, with the model estimating substantial savings in administration-related costs and a potential increase in treatment capacity. Because the comparison relied on a modeled counterfactual scenario, these findings should be confirmed in additional healthcare settings.
Additional Files
Published
Issue
Section
License
Copyright (c) 2026 Cristina Pittella

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)
